Home > Publications Database > Apheresis in Autoimmune Encephalitis and Autoimmune Dementia. > print

001     154378
005     20240411115843.0
024 7 _ |a 10.3390/jcm9092683
|2 doi
024 7 _ |a pmid:32824982
|2 pmid
024 7 _ |a pmc:PMC7563270
|2 pmc
024 7 _ |a altmetric:88799746
|2 altmetric
037 _ _ |a DZNE-2021-00231
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Roessling, Rosa
|0 P:(DE-2719)9001490
|b 0
|e First author
|u dzne
245 _ _ |a Apheresis in Autoimmune Encephalitis and Autoimmune Dementia.
260 _ _ |a Basel
|c 2020
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1712750863_11350
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 2077-0383 not unique: **3 hits**.
520 _ _ |a Autoimmune encephalitis (AE) is a rapidly progressive inflammatory neurological disease. Underlying autoantibodies can bind to neuronal surfaces and synaptic proteins resulting in psychiatric symptoms, focal neurological signs, autonomic dysfunction and cognitive decline. Early and effective treatment is mandatory to reduce clinical symptoms and to achieve remission. Therapeutic apheresis, involving both plasma exchange (PE) and immunoadsorption (IA), can rapidly remove pathogenic antibodies from the circulation, thus representing an important first-line treatment in AE patients. We here review the most relevant studies regarding therapeutic apheresis in AE, summarizing the outcome for patients and the expanding clinical spectrum of treatment-responsive clinical conditions. For example, patients with slowly progressing cognitive impairment suggesting a neurodegenerative dementia can have underlying autoantibodies and improve with therapeutic apheresis. Findings are encouraging and have led to the first ongoing clinical studies assessing the therapeutic effect of IA in patients with anti-neuronal autoantibodies and the clinical presentation of dementia. Therapeutic apheresis is an established and well tolerated option for first-line therapy in AE and, potentially, other antibody-mediated central nervous system diseases.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a NMDAR (N-Methyl-D-Aspartat)
|2 Other
650 _ 7 |a antibody
|2 Other
650 _ 7 |a apheresis
|2 Other
650 _ 7 |a autoimmune encephalitis
|2 Other
650 _ 7 |a immunoadsorption
|2 Other
650 _ 7 |a limbic encephalitis
|2 Other
650 _ 7 |a paraneoplastic
|2 Other
650 _ 7 |a plasma exchange
|2 Other
700 1 _ |a Prüß, Harald
|0 P:(DE-2719)2810931
|b 1
|e Last author
770 _ _ |a Apheresis in Neurological Disorders
773 _ _ |a 10.3390/jcm9092683
|g Vol. 9, no. 9, p. 2683 -
|0 PERI:(DE-600)2662592-1
|n 9
|p 2683
|t Journal of Clinical Medicine
|v 9
|y 2020
|x 2077-0383
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/154378/files/DZNE-2021-00231.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/154378/files/DZNE-2021-00231.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:154378
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001490
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810931
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 2 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-09-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN MED : 2021
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-09-04T08:13:34Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-09-04T08:13:34Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-17
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-17
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-05
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Encephalopathies
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1810003
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21